{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:59:13Z","timestamp":1788260353459,"version":"build-2803163510"},"reference-count":132,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jaci.2022.08.003","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T21:59:50Z","timestamp":1663624790000},"page":"1289-1301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["New insights in systemic lupus erythematosus: From regulatory T cells to CAR-T-cell strategies"],"prefix":"10.1016","volume":"150","author":[{"given":"Matteo","family":"Doglio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Del Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Snowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6117-5328","authenticated-orcid":false,"given":"Raffaella","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2022.08.003_bib1","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.08.003_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108907","article-title":"Systemic lupus erythematosus \u2013 are children miniature adults?","volume":"234","author":"Alexander","year":"2022","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib3","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrrheum.2016.137","article-title":"The global burden of SLE: prevalence, health disparities and socioeconomic impact","volume":"12","author":"Carter","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaci.2022.08.003_bib4","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1136\/annrheumdis-2017-211663","article-title":"Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016","volume":"76","author":"Tektonidou","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.08.003_bib5","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M17-0102","article-title":"46-year trends in systemic lupus erythematosus mortality in the United States, 1968 to 2013","volume":"167","author":"Yen","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2022.08.003_bib6","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","article-title":"Immunopathogenic mechanisms of systemic autoimmune disease","volume":"382","author":"Wahren-Herlenius","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2022.08.003_bib7","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nrneph.2016.71","article-title":"The role of neutrophils and NETosis in autoimmune and renal diseases","volume":"12","author":"Gupta","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jaci.2022.08.003_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000336","article-title":"Type I interferons in host defence and inflammatory diseases","volume":"6","author":"Crow","year":"2019","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.jaci.2022.08.003_bib9","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.4049\/jimmunol.2100339","article-title":"B cell activation and plasma cell differentiation are promoted by IFN-\u03bb in systemic lupus erythematosus","volume":"207","author":"Barnas","year":"2021","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib10","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nri3857","article-title":"Antibody-independent functions of B cells: a focus on cytokines","volume":"15","author":"Shen","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib11","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.4049\/jimmunol.165.10.5970","article-title":"Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus","volume":"165","author":"Odendahl","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1136\/ard.2008.096495","article-title":"HLA-DRhigh\/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus","volume":"69","author":"Jacobi","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.08.003_bib13","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1002\/art.23498","article-title":"Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95","volume":"58","author":"Jacobi","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2022.08.003_bib14","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3389\/fimmu.2021.635615","article-title":"Deep phenotyping of CD11c+ B cells in systemic autoimmunity and controls","volume":"12","author":"Rincon-Arevalo","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib15","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1038\/s41467-018-03750-7","article-title":"IL-21 drives expansion and plasma cell differentiation of autoreactive CD11chiT-bet+ B cells in SLE","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2022.08.003_bib16","doi-asserted-by":"crossref","unstructured":"Szelinski F, Stefanski AL, Wiedemann A, Schrezenmeier E, Rincon-Arevalo H, Reiter K, et\u00a0al. Antigen-experienced CXCR5-CD19 low B cells are plasmablast precursors expanded in SLE [published online ahead of print April 20, 2022]. Arthritis Rheumatol. https:\/\/doi.org\/10.1101\/2021.05.25.21257784","DOI":"10.1101\/2021.05.25.21257784"},{"key":"10.1016\/j.jaci.2022.08.003_bib17","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.3389\/fimmu.2021.667991","article-title":"BTLA expression and function are impaired on SLE B cells","volume":"12","author":"Wiedemann","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib18","first-page":"1655","article-title":"Pyruvate kinase M2 contributes to TLR-mediated inflammation and autoimmunity by promoting Pyk2 activation","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaci.2022.08.003_bib20","doi-asserted-by":"crossref","first-page":"230ra46","DOI":"10.1126\/scitranslmed.3008146","article-title":"Cell distance mapping identifies functional T follicular helper cells in inflamed human renal tissue","volume":"6","author":"Liarski","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2022.08.003_bib21","first-page":"1861","article-title":"Expanded circulating peripheral helper T cells in systemic lupus erythematosus: association with disease activity and B cell differentiation","volume":"58","author":"Makiyama","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaci.2022.08.003_bib22","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s41590-019-0398-x","article-title":"The immune cell landscape in kidneys of patients with lupus nephritis","volume":"20","author":"Arazi","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib23","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.08.003_bib24","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156341","article-title":"Single cell transcriptomics reveals distinct effector profiles of infiltrating T cells in lupus skin and kidney","volume":"7","author":"Dunlap","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaci.2022.08.003_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.108952","article-title":"Dysregulated protein kinase\/phosphatase networks in SLE T cells","volume":"236","author":"Su\u00e1rez-Rojas","year":"2022","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib26","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","article-title":"Autoimmunity and organ damage in systemic lupus erythematosus","volume":"21","author":"Tsokos","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.clim.2018.02.002","article-title":"Mechanistic aspects of epigenetic dysregulation in SLE","volume":"196","author":"Hedrich","year":"2018","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib28","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.4049\/jimmunol.1900760","article-title":"cAMP response element modulator \u03b1 induces dual specificity protein phosphatase 4 to promote effector T cells in juvenile-onset lupus","volume":"203","author":"Hofmann","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fimmu.2019.00159","article-title":"The regulatory T cell in active systemic lupus erythematosus patients: a systemic review and meta-analysis","volume":"10","author":"Li","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib30","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","article-title":"Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus","volume":"75","author":"von Spee-Mayer","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.08.003_bib31","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3109\/08916934.2013.801462","article-title":"Epigenetic regulation of cytokine expression in systemic lupus erythematosus with special focus on T cells","volume":"47","author":"Hedrich","year":"2014","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jaci.2022.08.003_bib32","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.celrep.2019.12.014","article-title":"The CD38\/NAD\/SIRTUIN1\/EZH2 axis mitigates cytotoxic CD8 T cell function and identifies patients with SLE prone to infections","volume":"30","author":"Katsuyama","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.jaci.2022.08.003_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000634","article-title":"Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria","volume":"9","author":"van Vollenhoven","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.jaci.2022.08.003_bib34","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.08.003_bib35","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/annrheumdis-2016-209519","article-title":"A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)","volume":"76","author":"van Vollenhoven","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.08.003_bib36","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.08.003_bib37","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/S0140-6736(19)30546-X","article-title":"Novel paradigms in systemic lupus erythematosus","volume":"393","author":"D\u00f6rner","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2022.08.003_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000785","article-title":"Antiphospholipid syndrome: state of the art on clinical practice guidelines","volume":"4","author":"Limper","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.jaci.2022.08.003_bib39","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/rheumatology\/keu482","article-title":"EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres","volume":"54","author":"Pamfil","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaci.2022.08.003_bib40","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 Update of the Joint European League Against Rheumatism and European Renal Association\u2013European Dialysis and Transplant Association (EULAR\/ERA\u2013EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.08.003_bib41","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.08.003_bib42","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2022.08.003_bib43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.08.003_bib44","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2022.08.003_bib45","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2022.08.003_bib46","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/annrheumdis-2021-eular.2570","article-title":"POS0698 BIIB059 demonstrated a consistent therapeutic effect on SRI-4 response across subgroups of participants with systemic lupus erythematosus in the LILAC phase 2 study","volume":"80","author":"Van Vollenhoven","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.08.003_bib47","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","article-title":"Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"60","author":"Furie","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaci.2022.08.003_bib48","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.08.003_bib49","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.08.003_bib50","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and safety of atacicept in patients with systemic lupus erythematosus","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2022.08.003_bib51","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","article-title":"Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019","volume":"54","author":"Duarte","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaci.2022.08.003_bib52","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1146\/annurev-med-070119-115617","article-title":"Hematopoietic stem cell transplantation for autoimmune disease","volume":"72","author":"Alexander","year":"2021","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jaci.2022.08.003_bib53","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2005-06-2269","article-title":"Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin","volume":"107","author":"Zand","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.08.003_bib54","first-page":"53","article-title":"Resetting the immune system with immunoablation and autologous haematopoietic stem cell transplantation in autoimmune diseases","volume":"34","author":"Alexander","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaci.2022.08.003_bib55","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrrheum.2017.7","article-title":"Haematopoietic stem cell transplantation for autoimmune diseases","volume":"13","author":"Swart","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaci.2022.08.003_bib56","series-title":"Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases","author":"Burt","year":"2021"},{"key":"10.1016\/j.jaci.2022.08.003_bib57","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s41409-018-0173-x","article-title":"Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus: effect of conditioning regimen on outcome","volume":"53","author":"Burt","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaci.2022.08.003_bib58","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1136\/ard.2010.148049","article-title":"Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus","volume":"70","author":"Illei","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.08.003_bib59","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/bmt.2011.185","article-title":"Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation","volume":"47","author":"Snowden","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaci.2022.08.003_bib60","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3389\/fimmu.2019.01570","article-title":"Allogeneic HSCT for autoimmune diseases: a retrospective study from the EBMT ADWP, IEWP, and PDWP Working Parties","volume":"10","author":"Greco","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib61","first-page":"2513","article-title":"Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus","volume":"31","author":"Khorshid","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaci.2022.08.003_bib62","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/sj.bmt.1705359","article-title":"Non-myeloablative allogeneic stem cell transplant in a patient with refractory systemic lupus erythematosus","volume":"37","author":"Lu","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaci.2022.08.003_bib63","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/bmt.2014.68","article-title":"Systemic lupus erythematosus complicated with thymoma and pure red cell aplasia (PCRA). CR of both complications following thymectomy and allogeneic haematopoietic SCT (HSCT), but persistence of antinuclear antibodies (ANA)","volume":"49","author":"Marmont","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaci.2022.08.003_bib64","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/sj.bmt.1703833","article-title":"Refractory Evans\u2019 syndrome treated with allogeneic SCT followed by DLI. Demonstration of a graft-versus-autoimmunity effect","volume":"31","author":"Marmont","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaci.2022.08.003_bib65","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bbmt.2007.03.001","article-title":"Allogeneic bone marrow transplantation in models of experimental autoimmune encephalomyelitis: evidence for a graft-versus-autoimmunity effect","volume":"13","author":"Van Wijmeersch","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaci.2022.08.003_bib66","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2022.08.003_bib67","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/blood-2018-99-117445","article-title":"Phase 1 study of CD19\/CD22 bispecific chimeric antigen receptor (CAR) therapy in children and young adults with B cell acute lymphoblastic leukemia (ALL)","volume":"132","author":"Schultz","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.08.003_bib68","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jaci.2022.08.003_bib69","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2022.08.003_bib70","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in\u00a0vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jaci.2022.08.003_bib71","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3389\/fimmu.2018.00507","article-title":"Extracellular NGFR spacers allow efficient tracking and enrichment of fully functional CAR-T cells co-expressing a suicide gene","volume":"9","author":"Casucci","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib72","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematol","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaci.2022.08.003_bib73","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.08.003_bib74","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2022-eular.1120","article-title":"OP0279 CAR-T cell treatment of refractory systemic lupus erythematosus\u2014safety and preliminary efficacy data from the first four patients","volume":"81","author":"Schett","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.08.003_bib75","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2022.08.003_bib76","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2022.08.003_bib77","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jaci.2022.08.003_bib78","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib79","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.omtm.2018.01.006","article-title":"A rapamycin-based GMP-compatible process for the isolation and expansion of regulatory T cells for clinical trials","volume":"8","author":"Fraser","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jaci.2022.08.003_bib80","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nri.2017.75","article-title":"The regulation of immune tolerance by FOXP3","volume":"17","author":"Lu","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib81","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3389\/fimmu.2012.00211","article-title":"Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity","volume":"3","author":"Barzaghi","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib82","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.immuni.2009.03.019","article-title":"Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor","volume":"30","author":"Miyara","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2022.08.003_bib83","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/cmi.2017.123","article-title":"TLR7, a third signal for the robust generation of spontaneous germinal center B cells in systemic lupus erythematosus","volume":"15","author":"Fan","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib84","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fimmu.2019.00043","article-title":"Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity","volume":"10","author":"Romano","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib85","doi-asserted-by":"crossref","first-page":"10113","DOI":"10.1073\/pnas.0711106105","article-title":"Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in\u00a0vitro and actively inhibit their maturation","volume":"105","author":"Onishi","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jaci.2022.08.003_bib86","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/mi.2015.66","article-title":"Induction of human IL-10-producing neutrophils by LPS-stimulated Treg cells and IL-10","volume":"9","author":"Lewkowicz","year":"2016","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib87","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/annrheumdis-2012-202216","article-title":"Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus","volume":"72","author":"Alexander","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.08.003_bib88","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41573-019-0041-4","article-title":"Next-generation regulatory T cell therapy","volume":"18","author":"Ferreira","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2022.08.003_bib89","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"Treg cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib90","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20953336","article-title":"Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis","volume":"12","author":"Peng","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.jaci.2022.08.003_bib91","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.immuni.2020.07.002","article-title":"Anti-inflammatory roles of glucocorticoids are mediated by Foxp3+ regulatory T cells via a miR-342-dependent mechanism","volume":"53","author":"Kim","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2022.08.003_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2021.713358","article-title":"Harnessing Treg homeostasis to optimize posttransplant\u00a0immunity: current concepts and future perspectives","volume":"12","author":"Ikegawa","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib93","first-page":"4062","article-title":"Mesenchymal stem cell therapy: hope for patients with systemic lupus erythematosus","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib94","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1073\/pnas.0903158107","article-title":"Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus","volume":"107","author":"Humrich","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jaci.2022.08.003_bib95","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.4049\/jimmunol.1400977","article-title":"IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells","volume":"193","author":"Mizui","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib96","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2022.08.003_bib97","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/S2665-9913(19)30018-9","article-title":"Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial","volume":"1","author":"Humrich","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jaci.2022.08.003_bib98","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and\u00a0safety\u00a0of\u00a0low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.08.003_bib99","doi-asserted-by":"crossref","unstructured":"Hernandez R, P\u00f5der J, LaPorte KM, Malek TR. Engineering IL-2 for immunotherapy of autoimmunity and cancer [published online ahead of print February 25, 2022]. Nat Rev Immunol. https:\/\/doi.org\/10.1038\/s41577-022-00680-w.","DOI":"10.1038\/s41577-022-00680-w"},{"key":"10.1016\/j.jaci.2022.08.003_bib100","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/d41573-021-00034-6","article-title":"Restoring IL-2 to its cancer immunotherapy glory","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2022.08.003_bib101","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/annrheumdis-2014-206506","article-title":"Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE","volume":"74","author":"Humrich","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2022.08.003_bib102","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/jir.2018.0016","article-title":"Interleukin-2 deficiency associated with renal impairment in systemic lupus erythematosus","volume":"39","author":"Shao","year":"2019","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.jaci.2022.08.003_bib103","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12865-019-0305-0","article-title":"Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17\/Treg cells in refractory SLE patients","volume":"20","author":"Zhao","year":"2019","journal-title":"BMC Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib104","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/art.40737","article-title":"Adoptive Treg cell therapy in a patient with systemic lupus erythematosus","volume":"71","author":"Dall\u2019Era","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2022.08.003_bib105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clim.2014.03.016","article-title":"Therapy of type 1 diabetes with CD4(+)CD25(high)CD127\u2212regulatory T cells prolongs survival of pancreatic islets\u2014results of one year follow-up","volume":"153","author":"Marek-Trzonkowska","year":"2014","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib106","doi-asserted-by":"crossref","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2022.08.003_bib107","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.3389\/fimmu.2020.622810","article-title":"Treg therapies revisited: tolerance beyond deletion","volume":"11","author":"Pilat","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib108","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2035117","article-title":"Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders \u2013 advances and challenges","volume":"18","author":"Goswami","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jaci.2022.08.003_bib109","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1084\/jem.20040139","article-title":"In\u00a0vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes","volume":"199","author":"Tang","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2022.08.003_bib110","doi-asserted-by":"crossref","first-page":"507","DOI":"10.4049\/jimmunol.163.1.507","article-title":"Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity","volume":"163","author":"Clay","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib111","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.jaci.2022.08.003_bib112","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011726","article-title":"Human antigen-specific regulatory T cells generated by T cell receptor gene transfer","volume":"5","author":"Brusko","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2022.08.003_bib113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2017.01313","article-title":"Avidity and bystander suppressive capacity of human regulatory T cells expressing de novo autoreactive T-cell receptors in type 1 diabetes","volume":"8","author":"Yeh","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib114","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaut.2017.01.001","article-title":"Generation of human islet-specific regulatory T cells by TCR gene transfer","volume":"79","author":"Hull","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jaci.2022.08.003_bib115","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood-2014-04-566786","article-title":"Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses","volume":"125","author":"Kim","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.08.003_bib116","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaut.2018.05.003","article-title":"Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells","volume":"92","author":"Kim","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jaci.2022.08.003_bib117","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/gt.2009.75","article-title":"Redirecting human CD4+CD25+ regulatory T cells from the peripheral blood with pre-defined target specificity","volume":"16","author":"Hombach","year":"2009","journal-title":"Gene Ther"},{"key":"10.1016\/j.jaci.2022.08.003_bib118","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1158\/0008-5472.CAN-10-0552","article-title":"In\u00a0vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy","volume":"71","author":"Lee","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaci.2022.08.003_bib119","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.136185","article-title":"CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD","volume":"5","author":"Imura","year":"2020","journal-title":"JCI insight"},{"key":"10.1016\/j.jaci.2022.08.003_bib120","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1172\/JCI82771","article-title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","volume":"126","author":"MacDonald","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2022.08.003_bib121","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/ajt.14185","article-title":"Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection","volume":"17","author":"Boardman","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jaci.2022.08.003_bib122","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/ajt.14175","article-title":"Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor","volume":"17","author":"Noyan","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jaci.2022.08.003_bib123","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood-2016-07-727834","article-title":"FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII","volume":"129","author":"Yoon","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2022.08.003_bib124","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.4049\/jimmunol.1701800","article-title":"Targeting antigen-specific B cells using antigen-expressing transduced regulatory T cells","volume":"201","author":"Zhang","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib125","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12910","article-title":"Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed\/refractory multiple myeloma","volume":"92","author":"Feng","year":"2020","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.jaci.2022.08.003_bib126","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2072","article-title":"Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma","volume":"3","author":"Lyman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaci.2022.08.003_bib127","doi-asserted-by":"crossref","first-page":"v12","DOI":"10.1093\/rheumatology\/keaa484","article-title":"New biomarkers in SLE: from bench to bedside","volume":"59","author":"Capecchi","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaci.2022.08.003_bib128","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1002\/ijc.33156","article-title":"Cost of decentralized CAR T-cell production in an academic nonprofit setting","volume":"147","author":"Ran","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jaci.2022.08.003_bib129","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jcyt.2020.08.007","article-title":"Comparison between centralized and decentralized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulation","volume":"23","author":"Lam","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jaci.2022.08.003_bib130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jaci.2022.08.003_bib131","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nm.3432","article-title":"Pathogenic conversion of Foxp3\u00a0+ T cells into TH17 cells in autoimmune arthritis","volume":"20","author":"Komatsu","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2022.08.003_bib132","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13075-022-02756-3","article-title":"\u2018Not at target\u2019: prevalence and consequences of inadequate disease control in systemic lupus erythematosus\u2014a multinational observational cohort study","volume":"24","author":"Kandane-Rathnayake","year":"2022","journal-title":"Arthritis Res Ther"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674922010569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674922010569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:38:20Z","timestamp":1758793100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674922010569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":132,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0091674922010569"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2022.08.003","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New insights in systemic lupus erythematosus: From regulatory T cells to CAR-T-cell strategies","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2022.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}